Results 201 to 210 of about 50,913 (300)

Prevalence of Benzodiazepine, Z‐Drug and Melatonin Use in Australian Residential Aged Care Facilities: A Systematic Review and Meta‐Analysis

Australasian Journal on Ageing, Volume 45, Issue 3, September 2026.
ABSTRACT Objectives To systematically examine the prevalence of, and factors associated with, benzodiazepine, Z‐drug and melatonin use in Australian residential aged care facilities (RACFs). Methods MEDLINE, Embase, CINAHL, PsycINFO, Scopus and International Pharmaceutical Abstracts were searched from January 2000 to February 2025 for studies reporting
Yuxing Joyce Liu, J. Simon Bell, Annie M. L. Ea, Mingxuan Cui, Ho Chan, Faiza Hoda, Amanda J. Cross   +6 more
wiley   +1 more source

On 3‐MMC: A Cathinone I Have Come to Know and Love

Anthropology of Consciousness, Volume 37, Issue 2, Fall 2026.
ABSTRACT This article attempts to complicate the mythology of a compound in a state of becoming. I will trace lightly its origins as a cultural disruptor and how I am implicated in this imperative. Introducing you to 3‐MMC will require multiple modes of storytelling and taking of liberties, drawing on literature reviews, practice‐based research, prose,
Carmen Ostrander
wiley   +1 more source

A Shift in Trust: An Analysis of the Use of AI Chatbots Among People Living With Bipolar Disorder

Bipolar Disorders, Volume 28, Issue 6, September 2026.
ABSTRACT Objectives To identify preliminary insights into the perceived utility and risks of commercially available AI chatbots such as ChatGPT used by individuals with severe mental illness (SMI), namely bipolar disorder, for self‐reflection and mental health support.
Katherine Bassil, Dido Prins, Hine van Os, Georg Starke, Eline de Groot, Annemieke Dols, Edwin van Dellen   +6 more
wiley   +1 more source

Correction to: Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. [PDF]

Psychopharmacology (Berl)
Rose JE, Frisbee S, Campbell D, Salley A, Claerhout S, Davis JM.   +5 more
europepmc   +1 more source

Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats

British Journal of Pharmacology, Volume 183, Issue 18, Page 5458-5475, September 2026.
Abstract Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission.
Carlos Núñez‐de la Calle, Lluna Careaga, Stefanie Malan‐Müller, Álvaro del Río‐García, Yaiza Trueba, Leticia Gil de Biedma‐Elduayen, Nuria Morales‐Puerto, Rebeca Vidal, Åsa Wiman, Sophie Erhardt, María Dolores Gutiérrez‐López, Esther O'Shea, María Isabel Colado   +12 more
wiley   +1 more source

Glutamatergic Modulators in Schizophrenia: Are We Ready to Move Beyond the Narrow Focus on Dopamine? A Potential Paradigm Shift in Psychopharmacology. [PDF]

Alpha Psychiatry
de Filippis R, Guinart D, Correll CU, Liparota G, Kishimoto T, De Fazio P.   +5 more
europepmc   +1 more source

‘I Call Them Our Village’: Experiences Of Caregivers in Ontario's Extensive Needs Service

Child: Care, Health and Development, Volume 52, Issue 5, September 2026.
ABSTRACT Background Children and youth with complex needs, including neurodevelopmental disabilities or acquired brain injuries and co‐occurring mental health and physical health diagnoses, often experience difficulties accessing care that they need.
Victoria Rombos, Zainab O. Salami, Nicholas Denomey, Genevieve Ferguson, Renee Baysarowich, Dennis Newhook, Stephanie Sutherland, Irene Drmic, Jordan Edwards, Srishti Sharma, Kathryn Decker, Tamara Milicevic, Melanie Penner   +12 more
wiley   +1 more source